LONDON: The global vaccine alliance Gavi announced on Monday its intention to allocate $600 million in soon-to-be-restored US funding to enhance malaria and other vaccination initiatives. The organization also plans to comply with US conditions regarding the gradual elimination of the preservative thimerosal from certain vaccines in its portfolio.
Board Decision Pending
Gavi stated that its board will ultimately decide how the funds are utilized, though malaria vaccination is expected to be a primary focus. The $600 million, approved by the US Congress for fiscal years 2025 and 2026, had been withheld by US Health Secretary Robert F. Kennedy Jr., who in June 2025 alleged that Gavi ignored safety concerns without providing evidence. The US had also not pledged future funding for Gavi.
Re-engagement Announced
Last week, US Secretary of State Marco Rubio indicated it was time to re-engage with Gavi, confirming that the $600 million would be released soon, though no specific date was provided. This funding is expected to significantly boost efforts against malaria, a disease that continues to claim hundreds of thousands of lives annually, primarily in Africa.
Gavi's commitment to phasing out thimerosal, a mercury-based preservative used in some vaccines, addresses longstanding US concerns. The alliance has already reduced its use in routine vaccines and will work to eliminate it from remaining products. This move aligns with global health standards and aims to reassure stakeholders about vaccine safety.
The restored funding marks a critical step in strengthening global immunization programs, particularly in low-income countries. Gavi's efforts are part of broader initiatives to combat infectious diseases and improve health outcomes worldwide.
